In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.
Topics include:
- How companies can balance the need to continually innovate while minimizing the failure rate
- How to realize revenue streams earlier in the process
- How to evaluate innovation based on potential business value
Panelists:
- Keith Lindenbaum, Partner, Foley & Lardner LLP
- David Kantaros, Partner, Foley & Lardner LLP
- Fouad Azzam, Ph.D., General Partner, Life Sciences Partners
- Jeff Barlow, Managing Director, Head of US Life Sciences Investment Banking, Canaccord Adams
- Stacy Coen, Senior Director of Business Development, Genzyme Corporation
- Robert Mashal, Ph.D., President & CEO, NKT Therapeutics Inc.
Related Insights
June 13, 2025
Foley Viewpoints
Eighth Circuit Affirms Summary Judgment to Insurer in Dispute with Construction Project Owner Over Lost Rental Income
On Monday, June 9, 2025, the Eighth Circuit Court of Appeals ruled that a Missouri real estate developer could not recover insurance…
June 13, 2025
Foley Viewpoints
Your Company Received an ICE Notice of Inspection — Now What?
“Worksite enforcement operations are going to massively expand,” according to a June 12, 2025, interview[1] with Border Czar Tom Homan….
June 13, 2025
Energy Current
Key Provisions of the One Big Beautiful Bill (H.R.1) Related to Foreign Ownership and Foreign Supply (FEOC)
Applicable Limitations on Tax Credits under Sections 48E, 45Y, and 45X: The below summary describes provisions in the One Big Beautiful…